Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis.

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Vyloy (zolbetuximab-clzb) - Astellas

Keytruda (pembrolizumab) - Merck (MSD)

Tevimbra (tislelizumab-jsgr) - BeOne Medicines

http://www.ncbi.nlm.nih.gov/pubmed/42748508

F Lordick; G Gourgioti; H Yang; K Shitara; M Oh; R H Getzenberg; R Ranganath; S J Klempner; S Y Rha; X Chai

Sep 17, 2026